Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients
European Journal of Cancer2017Vol. 81, pp. 237–239
Citations Over TimeTop 10% of 2017 papers
Related Papers
- → Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer(2019)2,789 cited
- → Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab(2016)21 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)